QEDDI
University-linked small-molecule drug discovery and development unit that translates academic biomedical research into preclinical drug candidates. Offers integrated hit-finding, medicinal chemistry, computational design, pharmacology, DMPK/PKPD, formulation and preclinical development with support for partnering, spin-out formation and early clinical enablement.
Industries
Nr. of Employees
small (1-50)
Products
Preclinical candidate for advanced prostate cancer (QED-203)
First-in-class small-molecule preclinical candidate developed for metastatic castration-resistant prostate cancer; progressed with preclinical development, process optimisation and safety studies to enable clinical progression.
Topical preclinical compound for prevention/treatment of skin cancer (Q-2361)
Topically delivered small-molecule program to prevent and treat skin cancers in immunosuppressed organ-transplant recipients; progressed through preclinical development with formulation and scale-up activities.
Preclinical candidate for advanced prostate cancer (QED-203)
First-in-class small-molecule preclinical candidate developed for metastatic castration-resistant prostate cancer; progressed with preclinical development, process optimisation and safety studies to enable clinical progression.
Topical preclinical compound for prevention/treatment of skin cancer (Q-2361)
Topically delivered small-molecule program to prevent and treat skin cancers in immunosuppressed organ-transplant recipients; progressed through preclinical development with formulation and scale-up activities.
Services
End-to-end discovery services including target validation, hit identification, medicinal chemistry, computational support, pharmacology, DMPK/PKPD profiling and preclinical development for academic and industry projects.
Formulation development (including topical formulations), stability testing and coordination with contract manufacturers to generate material and formulations suitable for preclinical testing.
End-to-end discovery services including target validation, hit identification, medicinal chemistry, computational support, pharmacology, DMPK/PKPD profiling and preclinical development for academic and industry projects.
Formulation development (including topical formulations), stability testing and coordination with contract manufacturers to generate material and formulations suitable for preclinical testing.
Expertise Areas
- Integrated small-molecule drug discovery
- Medicinal chemistry and SAR development
- Target validation and assay development
- Pharmacology, PK/PD and DMPK
Key Technologies
- High-throughput screening
- Fragment-based drug discovery
- Structure-guided drug design
- Structure-activity relationship (SAR) workflows
News & Updates
Announcement of a $1.25M investment to advance a first-in-class prostate cancer small-molecule candidate (QED-203) through key preclinical manufacturing and safety studies.
Announcement of a partnership to form a startup (Curlew Bio) to develop anti-inflammatory small molecules, leveraging QEDDI expertise and UniQuest funding.
Report on funding to advance a topical compound to prevent and treat skin cancer in transplant recipients through preclinical development and formulation work.
Collaboration with BioCurate to co-develop a novel inhibitor for neuropathic pain targeting two ion channels, using QEDDI discovery capabilities.
Report on a $2M grant to establish the Queensland Drug Discovery Alliance (QDDA) to align and grow small-molecule discovery capabilities across Queensland, including QEDDI.
Received $1.9M from Therapeutic Innovation Australia (NCRIS) to open the facility to researchers across Australia and expand services.
Announcement of a $1.25M investment to advance a first-in-class prostate cancer small-molecule candidate (QED-203) through key preclinical manufacturing and safety studies.
Announcement of a partnership to form a startup (Curlew Bio) to develop anti-inflammatory small molecules, leveraging QEDDI expertise and UniQuest funding.
Report on funding to advance a topical compound to prevent and treat skin cancer in transplant recipients through preclinical development and formulation work.
Collaboration with BioCurate to co-develop a novel inhibitor for neuropathic pain targeting two ion channels, using QEDDI discovery capabilities.
Report on a $2M grant to establish the Queensland Drug Discovery Alliance (QDDA) to align and grow small-molecule discovery capabilities across Queensland, including QEDDI.
Received $1.9M from Therapeutic Innovation Australia (NCRIS) to open the facility to researchers across Australia and expand services.